<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914550</url>
  </required_header>
  <id_info>
    <org_study_id>107003-3</org_study_id>
    <nct_id>NCT00914550</nct_id>
  </id_info>
  <brief_title>Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia</brief_title>
  <official_title>Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn if a blood test is helpful to the doctors in deciding
      whether you need antibiotic therapy for possible pneumonia. The blood test is called a
      Procalcitonin level and sometimes the test reflects infection with certain bacteria (germs).
      When the doctors learn the results of these blood tests, they may be able to stop some of the
      antibiotic medications that they may have given to the patients. The study is designed, so
      that on a randomized basis (50/50 chance) the results from measuring Procalcitonin will be
      given to the patients' doctor. When the doctor receives these results, he/she may use this
      information, along with other information, to decide whether to continue antibiotic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the usefulness of serum Procalcitonin level measured to guide the antibiotic
      treatment of patients with radiographic lung infiltrates.The subjects involved in the study
      will be divided in two arms ,study arm where the caregivers will know the result of
      Procalcitonin level and they can change /withheld the antibiotic for the subjects.In other
      arm only investigators will know the Procalcitonin level. We expect to enroll 100 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in antibiotic discontinuation as an effect of the caregivers learning Procalcitonin levels for the therapy of new radiographic lung infiltrates</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>Pneumonia</condition>
  <condition>Radiographic Lung Infiltrates</condition>
  <arm_group>
    <arm_group_label>Procalcitonin level, caregiver informed</arm_group_label>
    <description>Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procalcitonin level, caregiver informed</intervention_name>
    <description>Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms</description>
    <arm_group_label>Procalcitonin level, caregiver informed</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Procalcitonin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults admitted to Winthrop University Hospital with Lung Infiltrates undergoing antibiotic
        therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  New radiographic findings consistent with the presence of infiltrates

          -  Antibiotic therapy

        Exclusion Criteria:

          -  Critically ill patients on admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Niederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop-University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.winthrop.org</url>
    <description>Winthrop-University Hospital website</description>
  </link>
  <link>
    <url>http://thoracic.org/statements/resources/mtpi/idsaats-cap.pdf</url>
    <description>Guidelines on the management of Community-acquired Pneumonia by Infections Diseases Society of America and American Thoracic Society</description>
  </link>
  <reference>
    <citation>Niederman MS. Making sense of scoring systems in community acquired pneumonia. Respirology. 2009 Apr;14(3):327-35. Review.</citation>
    <PMID>19353770</PMID>
  </reference>
  <reference>
    <citation>Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, Martínez A, Esquinas C, Ramirez P, Torres A. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009 Jul;64(7):587-91. doi: 10.1136/thx.2008.105312. Epub 2009 Jan 8.</citation>
    <PMID>19131448</PMID>
  </reference>
  <reference>
    <citation>Niederman MS. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S127-32. doi: 10.1086/591393. Review.</citation>
    <PMID>18986278</PMID>
  </reference>
  <reference>
    <citation>Haeuptle J, Zaborsky R, Fiumefreddo R, Trampuz A, Steffen I, Frei R, Christ-Crain M, Müller B, Schuetz P. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):55-60. doi: 10.1007/s10096-008-0592-5. Epub 2008 Aug 2.</citation>
    <PMID>18677519</PMID>
  </reference>
  <reference>
    <citation>Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008 May;63(5):447-52. doi: 10.1136/thx.2007.086785. Epub 2008 Feb 1.</citation>
    <PMID>18245147</PMID>
  </reference>
  <reference>
    <citation>Ramirez P, Garcia MA, Ferrer M, Aznar J, Valencia M, Sahuquillo JM, Menéndez R, Asenjo MA, Torres A. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J. 2008 Feb;31(2):356-62. Epub 2007 Oct 24.</citation>
    <PMID>17959634</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B; ProHOSP study group. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007 Jul 5;7:102.</citation>
    <PMID>17615073</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.</citation>
    <PMID>16603606</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Winthrop University Hospital</investigator_affiliation>
    <investigator_full_name>Michael S. Niederman, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Lung Infiltrates</keyword>
  <keyword>Antibiotic discontinuation</keyword>
  <keyword>De-escalation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

